{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:51:50Z","timestamp":1760953910491},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T00:00:00Z","timestamp":1447891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/leu.2015.318","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T07:40:55Z","timestamp":1447918855000},"page":"1418-1421","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia"],"prefix":"10.1038","volume":"30","author":[{"given":"M S","family":"Zabriskie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C A","family":"Eide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N A","family":"Vellore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A D","family":"Pomicter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S L","family":"Savage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B J","family":"Druker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M W","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"O'Hare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,19]]},"reference":[{"key":"BFleu2015318_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O'Hare","year":"2012","unstructured":"O'Hare T, Zabriskie MS, Eiring AM, Deininger MW . Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12: 513\u2013526.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2015318_CR2","doi-asserted-by":"crossref","unstructured":"Ariad suspends ponatinib sales Cancer Discov 2014; 4: 6\u20137.","DOI":"10.1158\/2159-8290.CD-NB2013-163"},{"key":"BFleu2015318_CR3","first-page":"E11","volume":"20","author":"AJ Roth","year":"2014","unstructured":"Roth AJ . Reversing Halt, FDA reauthorizes sale of ponatinib. Am J Manag Care 2014; 20: E11.","journal-title":"Am J Manag Care"},{"key":"BFleu2015318_CR4","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783\u20131796.","journal-title":"N Engl J Med"},{"key":"BFleu2015318_CR5","doi-asserted-by":"crossref","unstructured":"Moslehi JJ, Deininger M . Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 2015; e-pub ahead of print 14 September 2015.","DOI":"10.1200\/JCO.2015.62.4718"},{"key":"BFleu2015318_CR6","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","volume":"125","author":"P Valent","year":"2015","unstructured":"Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P . Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors. Blood 2015; 125: 901\u2013906.","journal-title":"Blood"},{"key":"BFleu2015318_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 2014; 26: 428\u2013442.","journal-title":"Cancer Cell"},{"key":"BFleu2015318_CR8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40262-013-0068-3","volume":"52","author":"Y Chen","year":"2013","unstructured":"Chen Y, Tortorici MA, Garrett M, Hee B, Klamerus KJ, Pithavala YK . Clinical pharmacology of axitinib. Clin Pharmacokinet 2013; 52: 713\u2013725.","journal-title":"Clin Pharmacokinet"},{"key":"BFleu2015318_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4137\/CMO.S10594","volume":"7","author":"M Gross-Goupil","year":"2013","unstructured":"Gross-Goupil M, Francois L, Quivy A, Ravaud A . Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol 2013; 7: 269\u2013277.","journal-title":"Clin Med Insights Oncol"},{"key":"BFleu2015318_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/CMAR.S74202","volume":"7","author":"O Gunnarsson","year":"2015","unstructured":"Gunnarsson O, Pfanzelter NR, Cohen RB, Keefe SM . Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma. Cancer Manag Res 2015; 7: 65\u201373.","journal-title":"Cancer Manag Res"},{"key":"BFleu2015318_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature14119","volume":"519","author":"T Pemovska","year":"2015","unstructured":"Pemovska T, Johnson E, Kontro M, Repasky GA, Chen J, Wells P et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 2015; 519: 102\u2013105.","journal-title":"Nature"},{"key":"BFleu2015318_CR12","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1128\/MCB.02202-05","volume":"26","author":"IJ Griswold","year":"2006","unstructured":"Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006; 26: 6082\u20136093.","journal-title":"Mol Cell Biol"},{"key":"BFleu2015318_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1517\/14740338.2014.888413","volume":"13","author":"S Bracarda","year":"2014","unstructured":"Bracarda S, Castellano D, Procopio G, Sepulveda JM, Sisani M, Verzoni E et al. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. Expert Opin Drug Saf 2014; 13: 497\u2013510.","journal-title":"Expert Opin Drug Saf"},{"key":"BFleu2015318_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11523-014-0307-z","volume":"10","author":"BI Rini","year":"2015","unstructured":"Rini BI, Quinn DI, Baum M, Wood LS, Tarazi J, Rosbrook B et al. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol 2015; 10: 45\u201353.","journal-title":"Target Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2015318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2015318","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2015318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:05:21Z","timestamp":1684433121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,19]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFleu2015318"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.318","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,19]]},"assertion":[{"value":"19 November 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}